- Home
- MATV vs ABUS Comparison
MATV vs ABUS Comparison
Compare MATV & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATV
- ABUS
- Stock Information
- Founded
- MATV 1995
- ABUS 2005
- Country
- MATV United States
- ABUS United States
- Employees
- MATV N/A
- ABUS N/A
- Industry
- MATV Paper
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MATV Basic Materials
- ABUS Health Care
- Exchange
- MATV Nasdaq
- ABUS Nasdaq
- Market Cap
- MATV 671.4M
- ABUS 711.2M
- IPO Year
- MATV 1995
- ABUS N/A
- Fundamental
- Price
- MATV $11.55
- ABUS $4.46
- Analyst Decision
- MATV Strong Buy
- ABUS Strong Buy
- Analyst Count
- MATV 1
- ABUS 2
- Target Price
- MATV $10.00
- ABUS $5.00
- AVG Volume (30 Days)
- MATV 381.9K
- ABUS 930.7K
- Earning Date
- MATV 11-05-2025
- ABUS 11-10-2025
- Dividend Yield
- MATV 3.46%
- ABUS N/A
- EPS Growth
- MATV N/A
- ABUS N/A
- EPS
- MATV N/A
- ABUS N/A
- Revenue
- MATV $1,967,300,000.00
- ABUS $15,416,000.00
- Revenue This Year
- MATV $3.68
- ABUS $138.02
- Revenue Next Year
- MATV $2.82
- ABUS N/A
- P/E Ratio
- MATV N/A
- ABUS N/A
- Revenue Growth
- MATV N/A
- ABUS 53.23
- 52 Week Low
- MATV $4.34
- ABUS $2.71
- 52 Week High
- MATV $17.47
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- MATV 57.21
- ABUS 54.42
- Support Level
- MATV $10.41
- ABUS $4.26
- Resistance Level
- MATV $11.29
- ABUS $4.61
- Average True Range (ATR)
- MATV 0.48
- ABUS 0.20
- MACD
- MATV 0.08
- ABUS -0.01
- Stochastic Oscillator
- MATV 88.21
- ABUS 65.45
About MATV Mativ Holdings Inc.
Mativ Holdings Inc is a diversified producer of premium specialty papers and resin-based products. It manufactures and sells paper and reconstituted tobacco products to the tobacco industry as well as specialized paper products. The company operates in two segments namely Advanced Materials and Structures, which manufactures resin-based products used in specialty applications in the filtration, infrastructure and construction, transportation, industrial, and medical end-markets, and Engineered Papers, which produces cigarette papers and reconstituted tobacco products for cigarette and cigar manufacturers, as well as various other non-tobacco paper products.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.